Tag: Heart Failure
Empagliflozin Confers Kidney-Protective Benefits After Acute MI
Reduced risk seen for total hospitalizations for heart failure, total adverse events of heart failure or all-cause mortality
Semaglutide Reduces Risk for MACE in Patients With Obesity and Heart Failure
MACE, heart failure composite end point, cardiovascular death, and all-cause death all improved with semaglutide for patients with versus without heart failure
Study Reveals Heart Failure Risks in American Indian Communities
Older age, smoking, macroalbuminuria, microalbuminuria, previous MI, diabetes, and glycated hemoglobin predict risk
CMR-Modeled PCWP Independent Risk Factor for Heart Failure
Characteristics associated with elevated CMR-modeled PCWP include hypertension, BMI, age, male sex, alcohol consumption
Mitral Valve Surgery Linked to Lower Rates of Adverse Outcomes in AFMR
Surgery associated with significantly lower rate of heart failure hospitalization, all-cause mortality despite more severe disease status
Follow-Up Has Improved for AMI, Heart Failure Hospitalization
Disparities still persist in follow-up rates, with largest disparities seen between Black and White patients, Medicaid dual- versus non-dual-eligible
Digoxin, Beta-Blockers Have Equivalent Effects on Heart Rate in A-Fib
Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test
Large Geographic Variation Seen With Heart Failure Phenotypes
Global regional differences seen in patient characteristics, treatment, and outcomes
Second Recipient of Genetically Modified Pig Kidney Has Died
ADA: Semaglutide Similarly Effective in Men, Women With Obesity-Linked Heart Failure
Semaglutide reduces body weight to a greater extent in females; yields similar improvements in heart failure-related symptoms in both sexes
